17th JBF Symposium
Advanced Search

Session Details

SymposiumSymposium : ADA

[D2-B1]Advancing Immunogenicity Assessment: The Latest Topics in ADA/NAb Assays and the Reporting Standardization

Thu. Mar 5, 2026 9:00 AM - 10:40 AM JST
Thu. Mar 5, 2026 12:00 AM - 1:40 AM UTC
Conference Room 408/409(4th Floor)
Chairman:Hisanori Hara(B2S Life Sciences), Hiroyuki Shimizu(Tanabe Pharma Corporation)
9:00 AM - 9:25 AM JST(12:00 AM - 12:25 AM UTC)

[D2-B1-01]Considerations of ADA assay optimization for incretin peptide-based therapeutics in preclinical studies

*Ruoxuan Sun1, Janey Ronxhi1, Yipei Zhang1, Xiaobin Zhang1, Mark G Qian1 (1. Takeda Development Center Americas, Inc.)
Comment()
9:25 AM - 9:50 AM JST(12:25 AM - 12:50 AM UTC)

[D2-B1-02]Neutralizing Antibody Assay for an Antibody-Drug Conjugate: Killing or not Killing?

*Weifeng Xu1 (1. Merck & Co., Inc.)
Comment()
9:50 AM - 10:15 AM JST(12:50 AM - 1:15 AM UTC)

[D2-B1-03]ADA and NAb validation testing and reporting harmonization

*Heather Myler1, Kelli Phillips1 (1. Takeda Development Center Americas, Inc)
Comment()
10:15 AM - 10:40 AM JST(1:15 AM - 1:40 AM UTC)

[D2-B1-04]Systematic Assessment of S/N Ratios as Alternative for ADA Titers -Consideration from a different perspective-

*Hisanori Hara1, Ronald R Bowsher1 (1. B2S Life Sciences, LLC)
Comment()
Back to Category List